Actively Recruiting
An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis
Led by University of Copenhagen · Updated on 2022-04-19
335
Participants Needed
1
Research Sites
831 weeks
Total Duration
On this page
Sponsors
U
University of Copenhagen
Lead Sponsor
H
Hvidovre University Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death. The condition is associated with several other chronic liver diseases like autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hereditary hemochromatosis and alpha-1-antitrypsin deficiency and may also develop secondary to other diseases like inflammatory bowel disease and chronic pancreatitis. Diagnosing chronic liver diseases can be challenging and treatment may be limited. In-depth phenotyping at a tissue level may generate insight into the underlying pathophysiology of diseases and furthermore identify common as well as specific diagnostic biomarkers and future treatment targets of the diseases. We therefore undertake a study that evaluates patients with chronic liver diseases associated with hepatic steatosis.
CONDITIONS
Official Title
An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients or healthy controls aged 18 years or older who can give informed consent
- Suspected liver disease including non-alcoholic steatohepatitis
- Suspected liver disease including alcoholic steatohepatitis
- Suspected liver disease including autoimmune hepatitis
- Suspected liver disease including primary biliary cholangitis
- Suspected liver disease including primary sclerosing cholangitis
- Suspected liver disease including inflammatory bowel disease
- Suspected liver disease including polycystic ovary syndrome
- Suspected liver disease including hereditary haemochromatosis
- Suspected liver disease including chronic pancreatitis
- Suspected liver disease including cystic fibrosis
- Suspected liver disease including alpha-1 antitrypsin deficiency
You will not qualify if you...
- Patients with malignant diseases
- Patients with viral hepatitis
- Patients with human immunodeficiency virus
- Patients with contraindications to liver biopsy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hvidovre University Hospital
Hvidovre, Denmark, 2650
Actively Recruiting
Research Team
A
Anne-Sofie H Jensen, MD
CONTACT
L
Lise L Gluud, Professor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here